A role for P-glycoprotein in environmental toxicology
- PMID: 12746142
- DOI: 10.1080/10937400306466
A role for P-glycoprotein in environmental toxicology
Abstract
P-Glycoprotein (P-gp) is a transmembrane protein, playing significant roles in the process of drug discovery and development and in pest resistance to pesticides. P-gp affects absorption, disposition, and elimination of different compounds and is mainly expressed in intestines, liver, kidneys, heart, colon, and placenta. The expression of P-gp in the blood-brain barrier (BBB) has been associated with the restricted access of many compounds to the central nervous system. Generated knockout mice by disruption of mdr 1a gene, encoding for P-gp, showed that this protein was expressed in the BBB. The absence or the low levels of P-gp elevated drug concentrations in tissues and decreased drug elimination. P-gp is responsible for resistance of cells to agents, particularly the anticancer drugs, by removing these drugs from cells. Increased expression of P-gp is implicated in decreased HIV drug availability at certain intracellular sites. The role of P-gp in affecting efficacy and toxicity of environmental toxicants such as pesticides and heavy metals has not been adequately investigated. Studies showed that P-gp contributes to resistance to pesticides in certain pest species, and to decrease toxicity by removing compounds from cells in mammals. Placental drug-transporting P-gp plays a significant role in limiting the transport of toxicants such as potential teratogens to the fetus. Several in vitro or in vivo assays, including using P-gp knockout or naturally deficient mice, were described for testing P-gp modulators. The role of P-gp following concurrent exposure to more multiple compounds needs further research. P-gp modulators should be carefully used, since some modulators that reverse P-gp efflux action in vitro may lead to alterations of tissue function and increase toxicity of xenobiotics in normal tissues. Recent reports from the pharmaceutical studies on the significance of P-gp as transporters in altering the efficacy and toxicity clearly highlight the need for further research in interaction with environmental toxicants.
Similar articles
-
P-glycoprotein activity and biological response.Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):257-60. doi: 10.1016/j.taap.2005.03.027. Toxicol Appl Pharmacol. 2005. PMID: 16043202 Review.
-
P-glycoprotein and pharmacokinetics.Anticancer Res. 1995 Mar-Apr;15(2):331-6. Anticancer Res. 1995. PMID: 7763002 Review.
-
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.Prog Neurobiol. 2005 May;76(1):22-76. doi: 10.1016/j.pneurobio.2005.04.006. Prog Neurobiol. 2005. PMID: 16011870 Review.
-
Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.Placenta. 2006 Jun-Jul;27(6-7):602-9. doi: 10.1016/j.placenta.2005.05.007. Epub 2005 Sep 6. Placenta. 2006. PMID: 16143395
-
MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.Hematol Oncol Clin North Am. 1995 Apr;9(2):319-36. Hematol Oncol Clin North Am. 1995. PMID: 7642466 Review.
Cited by
-
Non-nutritive sweeteners in breast milk: perspective on potential implications of recent findings.Arch Toxicol. 2015 Nov;89(11):2169-71. doi: 10.1007/s00204-015-1611-9. Epub 2015 Oct 14. Arch Toxicol. 2015. PMID: 26462668 Free PMC article. No abstract available.
-
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.PLoS One. 2015 Mar 20;10(3):e0119255. doi: 10.1371/journal.pone.0119255. eCollection 2015. PLoS One. 2015. PMID: 25793771 Free PMC article.
-
Pathophysiological implications of neurovascular P450 in brain disorders.Drug Discov Today. 2016 Oct;21(10):1609-1619. doi: 10.1016/j.drudis.2016.06.004. Epub 2016 Jun 14. Drug Discov Today. 2016. PMID: 27312874 Free PMC article. Review.
-
Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.Eur J Hum Genet. 2013 Dec;21(12):1436-41. doi: 10.1038/ejhg.2013.25. Epub 2013 Feb 27. Eur J Hum Genet. 2013. PMID: 23443032 Free PMC article.
-
Chalcone Derivatives as Potential Inhibitors of P-Glycoprotein and NorA: An In Silico and In Vitro Study.Biomed Res Int. 2022 Mar 26;2022:9982453. doi: 10.1155/2022/9982453. eCollection 2022. Biomed Res Int. 2022. PMID: 35378788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous